BOSTON (AP) _ Keryx Biopharmaceuticals Inc. (KERX) on Wednesday reported a loss of $30.4 million in its fourth quarter.
On a per-share basis, the Boston-based company said it had a loss of 26 cents.
The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 18 cents per share.
The biopharmaceutical company posted revenue of $18.7 million in the period, surpassing Street forecasts. Three analysts surveyed by Zacks expected $17.2 million.
For the year, the company reported that its loss widened to $163.4 million, or $1.43 per share. Revenue was reported as $60.6 million.
The company's shares closed at $4.10. A year ago, they were trading at $5.41.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on KERX at https://www.zacks.com/ap/KERX